.png){kind=small}
.png){kind=small}
BackTable / Urology / Contributor
Dr. Aditya Bagrodia
Genioturinary Oncologist
Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Listen to Dr. Aditya Bagrodia on the BackTable Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Aditya Bagrodia and get practical advice on how to build your practice by listening to the BackTable Podcast.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
About Dr. Aditya Bagrodia
Aditya Bagrodia, M.D., is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Dr. Bagrodia holds a bachelor of science degree from Rhodes College. While earning a medical degree with highest honors at the University of Tennessee Health Sciences Center, he was awarded a Doris Duke Clinical Research Fellowship at UT Southwestern Medical Center.
After completing his residency in urology at UT Southwestern, he received advanced training in urologic oncology through a fellowship at Memorial Sloan Kettering Cancer Center, where he was awarded a Urology Care Foundation Research Scholars Grant by the American Urological Association.
Dr. Bagrodia’s clinical practice focuses on treating all urologic malignancies, including adrenal, upper tract, renal, bladder, prostate, penile, and testicular cancers. He has expertise in complex multidisciplinary management and minimally invasive approaches to urologic surgery.
Dr. Bagrodia has conducted extensive research in urologic oncology, primarily in biomarker profiles and molecular signatures of urologic tumors as predictors of clinical outcomes. He is funded through competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT), intramural research grants, and the National Institutes of Health.
Both his clinical practice and research centers on patients with germ cell tumors (most commonly testicular cancer). His laboratory focuses on sequencing efforts to understand tumor evolution and heterogeneity in germ cell tumors and identifying novel biomarkers to recognize occult metastatic disease. The Bagrodia lab also conducts experiments in cell lines, zebrafish germ cell tumor models, and mice to understand the biologic implications of genetic alterations that are seen exclusively among patients with cisplatin-resistance disease. He is actively working on molecular biomarkers to identify minimal residual disease burden. On the clinical side, Dr. Bagrodia is actively involved in understanding and overcoming unique socioepidemiologic considerations that adversely impact oncologic outcomes in patients with germ cell tumors. He is also the principal investigator for several germ cell tumor-directed clinical trials at UT Southwestern (including NCT03426865 and NCT02537548).
Dr. Bagrodia is the principal author or co-author of more than 100 articles in peer-reviewed publications such as Journal of Clinical Oncology, Nature Genetics, European Urology, Journal of Urology, Urologic Oncology, and Urology. He is also a reviewer for many of these publications, as well as for the British Journal of Urology, Journal of Clinical Pathology, and Annals of Surgical Oncology.
Learn more by visiting Dr. Aditya Bagrodia's practice:
Podcasts Featuring Dr. Aditya Bagrodia
.png){kind=small}
Urology Episode #237
What if the key to better cancer outcomes lies not just in surgery or chemotherapy, but also in mindfulness, movement, and diet? In this episode of the BackTable Tumor Board, host Dr. Aditya Bagrodia interviews urologic oncologist Dr. Viraj Master, Professor of Urology at Emory University, about his role in developing the integrative oncology and survivorship service line at Winship Cancer Institute.
.png){kind=small}
Tumor Board Episode #15
What if the key to better cancer outcomes lies not just in surgery or chemotherapy, but also in mindfulness, movement, and diet? In this episode of the BackTable Tumor Board, host Dr. Aditya Bagrodia interviews urologic oncologist Dr. Viraj Master, Professor of Urology at Emory University, about his role in developing the integrative oncology and survivorship service line at Winship Cancer Institute.
Tumor Board Episode #12
What does it take to deliver truly personalized, multidisciplinary care in testicular cancer? Get an inside look in this episode of BackTable Tumor Board, where renowned testicular cancer experts Dr. Nabil Adra and Dr. Richard Matulewicz join host Dr. Aditya Bagrodia for a virtual tumor board session on the nuanced management of germ cell tumors.
Urology Episode #227
What does it take to deliver truly personalized, multidisciplinary care in testicular cancer? Get an inside look in this episode of BackTable Urology, where renowned testicular cancer experts Dr. Nabil Adra and Dr. Richard Matulewicz join host Dr. Aditya Bagrodia for a virtual tumor board session on the nuanced management of germ cell tumors. This episode was produced in collaboration with the Society of Urologic Oncology.
Urology Episode #224
Urology was recently named the most burned out specialty in the medical field – a title that we’re not particularly proud of. How can we better support ourselves and one another, and take real steps towards improving career satisfaction and mental health within our specialty? In this episode of the BackTable Urology Podcast, Dr. Nishant Patel, a urologist from San Diego bravely shares his personal struggles with depression, substance abuse, and suicidality with host Dr. Aditya Bagrodia; and how he overcame the lowest points in his career.
Urology Episode #210
What is the role of androgen deprivation therapy (ADT) in prostate cancer treatment? In this episode of the BackTable Urology Podcast, Dr. Rana McKay, a medical oncologist from UC San Diego, joins host Dr. Aditya Bagrodia to discuss the administration of ADT and other management strategies for prostate cancer.
Urology Episode #209
Are you a private practice urologist looking to build your bladder cancer service lines? In this episode of the BackTable Urology Podcast, Dr. Tom Jayram, urologist from Nashville joins host Dr. Aditya Bagrodia to discuss the latest advancements in non-muscle invasive bladder cancer treatment. The conversation focuses on the unique experiences and practical considerations in managing this complex condition in the community setting.
Urology Episode #207
How can urologists run clinical trials efficiently while improving enrollment and reducing costs? In this episode of the BackTable Urology Podcast, Dr. Behfar Ehdaie, a urologic oncologist at Memorial Sloan Kettering Cancer Center, joins host Dr. Aditya Bagrodia to discuss methods and practical implementation strategies for clinical trials in urology.
Urology Episode #206
Have you checked out the AUA/ASTRO/SUO’s recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management.
Urology Episode #204
Stay up to date in your bladder cancer practice with this insightful episode of the BackTable Urology podcast, developed in collaboration with the Society of Urologic Oncology. Dr. Betsy Koehne (University of Wisconsin) and Dr. Amir Salmasi (UC San Diego) talk through the contemporary management of low and intermediate-risk non-muscle-invasive bladder cancer.
Urology Episode #203
Recent research is changing how we manage low risk prostate cancer. In this BackTable Urology Podcast episode, Dr. Dan Lin, a urologist at the University of Washington, walks through contemporary diagnosis, surveillance, and management of Grade Group 2 prostate cancer with host Dr. Aditya Bagrodia.
Urology Episode #201
Retroperitoneal lymph node dissection (RPLND) for testicular cancer can be a challenging surgery, even for the most experienced urologic oncologists. In part one of this special two-part series, host Dr. Aditya Bagrodia invites Society of Urologic Oncologists (SUO) members Dr. Timothy Masterson (Indiana University) and Dr. Robert Hamilton (Princess Margaret Hospital/University of Toronto) to cover current approaches to post-chemotherapy RPLND.
Urology Episode #200
Biochemical recurrence of prostate cancer can be difficult to diagnose and treat. In this episode of BackTable Urology, where Dr. Aditya Bagrodia hosts Dr. Amar Kishan, a genitourinary radiation oncologist at UCLA, to discuss the complexities of biochemical recurrence and local failure after radiation therapy for prostate cancer.
Urology Episode #197
Frustrated with stone retrieval after a long lithotripsy case? In this episode of the BackTable Urology Podcast, host Aditya Bagrodia, MD, and guest Roger Sur, MD, director of the Comprehensive Kidney Stone Center at UC San Diego Health, delve into the latest technological advancements in the treatment of kidney stones. The episode focuses on the CVAC (continuous vacuum aspiration and irrigation) device as a suction platform for endourologists.
Urology Episode #189
Did you know that robotic prostatectomy has its roots in both the immigrant experience and the renowned manufacturing legacy of Detroit? In this episode of BackTable Urology, Dr. Mani Menon, a pioneer in robotic surgery, joins Dr. Aditya Bagrodia to discuss the development of robotic prostatectomy technology.
Urology Episode #181
It can be tough to avoid burnout, stay motivated, and retain your passion for patient care when facing the day-to-day challenges of medical practice. In this episode of the BackTable Urology Podcast, Dr. Alexander Kutikov from Fox Chase Cancer Center discusses keys to developing a sustainable and fulfilling career within urology.
.png){kind=small}
.png){kind=small}
.png){kind=small}
Articles Featuring Dr. Aditya Bagrodia
Urology
Compared to resection or radiation, focal therapy may offer a less invasive and more precise treatment option for prostate cancer patients. Who is the ideal patient for prostate cancer focal therapy? Which focal therapy modality is best? How do we optimize care after focal therapy to ensure that recurrence is managed effectively?
Urology
Advancements in genomics and imaging are transforming prostate cancer diagnosis and treatment by reducing overdiagnosis and personalizing treatment. Learn more about the integration of genomic tests and imaging techniques to help distinguish between benign conditions and clinically significant cancers.
Urology
Radical therapy remains the cornerstone in the treatment of high-risk prostate cancer, encompassing modalities such as radical prostatectomy and brachytherapy. Criteria for the high-risk prostate cancer designation typically include a Gleason score ranging from 8 to 10, grade 4 or 5, or PSA levels surpassing 20.
Get in touch!
We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Podcasts
Topics
More Contributors
Dr. Neeraj Agarwal
Dr. Piyush Agarwal
Dr. Andrea Apolo
Rick Bangs
Dr. Kelly Bree
Dr. Sam Chang